Bifogade filer
PDF
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Oslo, Norway, February 12th, 2025 - Lytix Biopharma today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/598,719 with the title "Immune Checkpoint Inhibitor Combinations".
This U.S. Patent will not only fortify Lytix Biopharma's intellectual property portfolio by protecting the use of LTX-315 in conjunction with PD-1 immune checkpoint inhibitor but also enhances our competitive edge in the burgeoning U.S. pharmaceutical market. The patent will extend the effective patent life of LTX-315, enabling us to secure our market position in the U.S. and maximize the value of our clinical programs. Patent with similar protection have been granted previously in other jurisdictions, thereby positioning Lytix at the forefront of cancer immunotherapy development.
LTX-315 is currently being evaluated in two ongoing Phase II clinical trials in combination with anti-PD-1 antibodies:
- ATLAS-IT-05 - Investigating LTX-315 in combination with pembrolizumab in late-stage metastatic melanoma patients who have failed prior anti-PD-1/PD-L1 treatment.
- NeoLIPA - A neoadjuvant trial at Oslo University Hospital assessing LTX-315 with pembrolizumab in patients with earlier-stage, resectable melanoma.
"We are pleased to have received this Notice of Allowance in the United States, reinforcing our competitive position in the world's largest pharmaceutical market," said Baldur Sveinbjørnsson, CSO of Lytix Biopharma. "This patent will further strengthen our business case as securing global intellectual property rights is of critical importance for our technology platform and the long-term value generation of the company."
For any questions, please contact:
Gjest Breistein, CFO
gjest.breistein@lytixbiopharma.com
+47 952 60 512
About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.